Afinum uses cookies to improve the quality of the website. If you continue browsing the site, you consent to the use of cookies.
I agreeFollowing a very successful growth path, AFINUM Achte Beteiligungsgesellschaft mbH & Co. KG (“Afinum”) has sold its stake in evitria Group (“evitria”). Atlas Antibodies AB, a portfolio company of Patricia Industries, acquires all shares in evitria from Afinum and minority shareholders including SHS Capital. evitria is a global leader in the field of transient CHO cell antibody expression with an international customer portfolio of leading biopharma companies in therapeutic and diagnostic antibody research.
During the holding period, Afinum accompanied, among other strategic initiatives, the succession and transfer of operations from the founder of the company to an independent management team and the creation of a sustainable organizational structure. Under the leadership of Dr. Christian Eberle, the CEO who came on board as part of the succession plan, evitria’s growth and internationalization course was accelerated very successfully. To capture the international market potential of the evitria technology platform and increase market penetration in Europe and the USA, an international sales organization was created with employees in the USA, UK, and Denmark. In addition, taking advantage of the strong positioning in the therapeutic antibody market, the company also entered the equally attractive and high-growth market for diagnostic antibodies. On the operational side, the technology platform was further developed, and production capacities were significantly expanded, also through further automation. Financial management was improved through the implementation of an adequate ERP system and the professionalization of reporting structures. Overall, the platform created over the holding period is – particularly in conjunction with the new owner Atlas Antibodies – excellently positioned to continue the successful and sustainable growth path and further cement its leading global position. The existing management team will remain fully on board under the new owner.
The transaction is already the second highly successful divestment of AFINUM Achte Beteiligungsgesellschaft mbH & Co. KG in the current year 2021.